aetherAI vs Indica Labs HALO AI

Indica Labs sells three products under the HALO name. HALO AI is a research add-on, a train-by-example classifier, and Indica claims deployments in all top 20 pharma companies. HALO AP Dx is the case-management platform cleared for primary diagnosis under K232833 in May 2024 and K252762 in November 2025, with the Aperio GT 450 DX and Hamamatsu NanoZoomer S360MD scanners, which suits labs already scanning on those models. HALO Prostate AI is CE-IVD marked to detect and grade prostate adenocarcinoma in core needle biopsies. Leica Biosystems is exclusive reseller of Indica's image management products and made a strategic investment in January 2025.

Where CE-IVD prostate grading is the requirement, aetherAI trails. The product line on its About page is Hema, Endo and aetherSlide, with Taiwan TFDA approval for the first two. A biopharma team quantifying IHC stains could buy either, since the aetherAI homepage lists IHC quantification and cell counting apps and the About page names Novartis Taiwan, ACT Genomics and Ono Pharmaceutical as partners.